Long-term protection from a meningococcal vaccine
Part of Infections clinical trials.
This study checks whether the MenFive™ vaccine still protects against meningococcal disease more than five years after vaccination. It aims to see how long the immune response lasts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have received the MenFive™ vaccine more than five years ago
- You must provide written permission (consent) to join the study
- You must not have had meningococcal disease since being vaccinated
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new meningococcal conjugate vaccine (EG-MCV4) in healthy adults to see how well the body's immune system responds and if it's safe. If you qualify, you'd help researchers learn if this vaccine can prevent meningococcal disease.
This study tests an experimental vaccine to protect babies and toddlers from meningitis (a serious infection of the brain and spinal cord). It checks how well the vaccine works and how safe it is in young children.
This study tests a new vaccine that may protect against several types of meningococcal bacteria, which can cause serious infections like meningitis. It is given as a single shot to healthy people aged 2 to 59 years.
This study checks if antibodies from earlier childhood vaccines (IPV, MMR, and hepatitis A) remain in the body five years later. It aims to understand how long protection may last.
This trial tests a vaccine that protects against four types of meningococcal bacteria (groups A, C, W, and Y) in healthy babies aged 3 to 5 months. The vaccine is given to help prevent meningitis and other serious infections.
This trial tests a new meningitis vaccine (GNG-DE) to see how well it works compared to a vaccine already on the market. It might help protect you or your child from meningococcal disease.
Hear when a new Meningoccocal Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.